3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
1278
Carcinoma, Non-Small-Cell Lung
927
Prostatic Neoplasms
729
Neoplasms
633
Multiple Myeloma
554
Lymphoma
540
Colorectal Neoplasms
530
Lung Neoplasms
515
Leukemia
498
Leukemia, Myeloid, Acute
474
Neoplasm Metastasis
471
Melanoma
426
Lymphoma, Non-Hodgkin
420
Ovarian Neoplasms
417
Leukemia, Lymphocytic, Chronic, B-Cell
386
Pancreatic Neoplasms
373
Recurrence
338
Precursor Cell Lymphoblastic Leukemia-Lymphoma
329
Head and Neck Neoplasms
307
Lymphoma, Large B-Cell, Diffuse
295
Glioblastoma
294
Myelodysplastic Syndromes
288
Lymphoma, Follicular
287
Brain Neoplasms
287
Stomach Neoplasms
282
Carcinoma, Renal Cell
268
Carcinoma, Hepatocellular
262
Hodgkin Disease
261
Rectal Neoplasms
256
Sarcoma
250
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Completed
×
Advanced Unresectable or Metastatic Solid Malignancy
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts